TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21417118

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT (permanent)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prime & Bond NT (primary)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single Bond (permanent)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Single Bond (primary)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Excite DSC (permanent)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Excite DSC (primary)
Number of subjects: 24
Study: 17906162

Group type: EXPERIMENTAL
Intervention: DRSP/E2
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15652830

Group type: EXPERIMENTAL
Intervention: Preserved timolol 0.5%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Preservative-free timolol 0.5%
Number of subjects: 20
Study: 11856083

Group type: EXPERIMENTAL
Intervention: Topical mononitrate hydrogel (0.2% isosorbide‐5‐mononitrate), applied twice daily for 3 weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo gel treatment
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Topical mononitrate hydrogel
Number of subjects: 19
Study: 10667099

Group type: EXPERIMENTAL
Intervention: Treatment A: 20 MUI of penicillin G per day for 3 weeks, infused over 4 hours
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Treatment B: 30 MUI of penicillin G per day for 10 days, infused over 6 hours
Number of subjects: 16
Study: 7548778

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil 100 mg tablet
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cefpodoxime proxetoxil oral solution (2 mg/mL)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetoxil oral solution (100 mg) with high-fat meal
Number of subjects: 11
Study: 1972140

Group type: EXPERIMENTAL
Intervention: Fenoldopam (0.05 microgram/kg/min i.v.)
Number of subjects: 16
Study: 475366

Group type: EXPERIMENTAL
Intervention: Cefaclor 1000 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefadroxil 1000 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CGP 9000 1000 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cephalexin 1000 mg (empty stomach)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cephalexin 1000 mg (with breakfast)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cefadroxil 1000 mg (with breakfast)
Number of subjects: 12
Study: 30719873

Group type: EXPERIMENTAL
Intervention: Large volume multi-use spacer
Number of subjects: 32

Group type: COMPARATOR
Intervention: Small volume disposable spacer
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Any spacer at 400 µg of salbutamol
Number of subjects: 32
Study: 30585458

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Zusanli (ST 36) and Neiguan (PC 6), stimulation at 2 Hz for 30 min, twice after surgery at 6-hour intervals.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional treatment only (control group).
Number of subjects: 40
Study: 27291997

Group type: EXPERIMENTAL
Intervention: Olaratumab (15 mg/kg) plus doxorubicin (75 mg/m²)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Doxorubicin (75 mg/m²) alone
Number of subjects: 148
Study: 25274252

Group type: EXPERIMENTAL
Intervention: exercise only
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: rigid anti-pronation tape and exercise
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: elastic anti-pronation tape and exercise
Number of subjects: 45
Study: 22762137

Group type: EXPERIMENTAL
Intervention: Glycyrrhizin 5×/week
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Glycyrrhizin 3×/week
Number of subjects: 379

Group type: COMPARATOR
Intervention: Placebo 5×/week
Number of subjects: 379
Study: 20883410

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Non-tamoxifen treatment
Number of subjects: 9
Study: 17628686

Group type: EXPERIMENTAL
Intervention: argon laser trabeculoplasty plus betaxolol
Number of subjects: 255

Group type: COMPARATOR
Intervention: no immediate treatment
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: higher baseline IOP
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: lower baseline IOP
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: baseline predictors
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: lower ocular systolic perfusion pressure
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: cardiovascular disease history (higher baseline IOP)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: lower systolic blood pressure (lower baseline IOP)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: IOP levels at follow‐up
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: disc hemorrhages
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: thinner central corneal thickness (CCT)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: thinner CCT (higher baseline IOP)
Number of subjects: 255
Study: 15982124

Group type: EXPERIMENTAL
Intervention: Opponent color pairs (e.g., the word BLUE in yellow)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonopponent color pairs (e.g., BLUE in red)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Farnsworth‐Munsell 100‐Hue Test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neural network simulations
Number of subjects: 0
Study: 12699401

Group type: EXPERIMENTAL
Intervention: Pranlukast 225mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pranlukast 225mg twice daily plus halved dosage of inhaled corticosteroid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pranlukast
Number of subjects: 0
Study: 11235009

Group type: EXPERIMENTAL
Intervention: Wobble board training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Jump landing training
Number of subjects: 44

Group type: COMPARATOR
Intervention: No training (Control)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All groups (including Wobble board, Jump landing, and Control)
Number of subjects: 44
Study: 9139306

Group type: EXPERIMENTAL
Intervention: Red palm oil (RPO) supplement (2400 mu g of beta-carotene)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (600 mu g of oral vitamin A palmitate)
Number of subjects: 24
Study: 1479004

Group type: EXPERIMENTAL
Intervention: GIFT
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ovarian stimulation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ovarian stimulation (AID)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ovarian stimulation (non-AID)
Number of subjects: 50
Study: 3909379

Group type: EXPERIMENTAL
Intervention: Selenium (256 micrograms daily in selenium-enriched yeast)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30658773

Group type: EXPERIMENTAL
Intervention: Closed-suction drainage device (drain group, n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No drain (control group, n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control cohort
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Drain cohort
Number of subjects: 100
Study: 28900690

Group type: EXPERIMENTAL
Intervention: Community Treatment Orders (CTOs)
Number of subjects: 114
Study: 26549704

Group type: EXPERIMENTAL
Intervention: Testosterone topical solution 2% (60 mg daily, applied to axillae)
Number of subjects: 148
Study: 24462419

Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 75

Group type: COMPARATOR
Intervention: Aceclofenac
Number of subjects: 75
Study: 22474059

Group type: EXPERIMENTAL
Intervention: 0.3 mg rtPA
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 1 mg rtPA
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 3 mg rtPA
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 19664255

Group type: EXPERIMENTAL
Intervention: Brief structured advice
Number of subjects: 744

Group type: EXPERIMENTAL
Intervention: Brief lifestyle counselling
Number of subjects: 744

Group type: COMPARATOR
Intervention: Leaflet-only control group
Number of subjects: 744
Study: 17578505

Group type: EXPERIMENTAL
Intervention: Sirolimus-based immunosuppression
Number of subjects: 32

Group type: COMPARATOR
Intervention: Calcineurin inhibitor-based immunosuppression
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine
Number of subjects: 32
Study: 15159685

Group type: EXPERIMENTAL
Intervention: Acute pancreatitis
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Fractures
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Both pain groups (acute pancreatitis and fractures)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group (patients without pain)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 3
Study: 12622078

Group type: EXPERIMENTAL
Intervention: Chinese herb group
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study: 9792567

Group type: EXPERIMENTAL
Intervention: Flutter therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard manual chest physiotherapy (CPT)
Number of subjects: 22
Study: 7521992

Group type: EXPERIMENTAL
Intervention: Discontinuation of antithyroid drugs 6 days before radioiodine therapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Radioiodine therapy (131I)
Number of subjects: 21

Group type: COMPARATOR
Intervention: No antithyroid drugs (control group)
Number of subjects: 21
Study: 2674262

Group type: EXPERIMENTAL
Intervention: Zaditen (ketotifen), 1.0 mg twice daily
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Zaditen (ketotifen)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 834152

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 3.2 g daily for 4 days
Number of subjects: 26

Group type: COMPARATOR
Intervention: Indomethacin (ID) 300 mg daily for 4 days
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Acute Acetylsalicylic acid (ASA) 1.5 g
Number of subjects: 26

Group type: COMPARATOR
Intervention: Acute Indomethacin (ID) 100 mg
Number of subjects: 26
Study: 31354089

Group type: EXPERIMENTAL
Intervention: Anticoagulation plus pharmacomechanical catheter-directed thrombolysis (PCDT)
Number of subjects: 692

Group type: COMPARATOR
Intervention: Anticoagulation
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Valvular reflux at 12 months
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: CFV non-compressibility at 1 month
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Valvular reflux prevalence
Number of subjects: 692
Study: 28455082

Group type: EXPERIMENTAL
Intervention: Bilateral salpingectomy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Tubal ligation
Number of subjects: 46
Study: 26286203

Group type: EXPERIMENTAL
Intervention: GSK961081 (batefenterol) 100 μg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK961081 (batefenterol) 400 μg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK961081 (batefenterol) 800 μg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK961081 (batefenterol) 100 μg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK961081 (batefenterol) 200 μg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSK961081 (batefenterol) 400 μg twice daily
Number of subjects: 0
Study: 24722530

Group type: EXPERIMENTAL
Intervention: Intraarterial (131)I-lipiodol (2,200 MBq)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Unlabeled lipiodol
Number of subjects: 58
Study: 21852093

Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (BUP/NX)
Number of subjects: 150
Study: 20014651

Group type: EXPERIMENTAL
Intervention: Conversing with each other on rigid surface
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conversing with confederates on rigid surface
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Conversing with each other on nonrigid surface
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conversing with confederates on nonrigid surface
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Conversing on nonrigid surface
Number of subjects: 2
Study: 17516972

Group type: EXPERIMENTAL
Intervention: Tight control (target dBP, 85 mmHg)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Less tight control (target dBP, 100 mmHg)
Number of subjects: 132
Study: 14736130

Group type: EXPERIMENTAL
Intervention: Zaleplon (10 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11194219

Group type: EXPERIMENTAL
Intervention: Educational and social support intervention (n = 250)
Number of subjects: 502

Group type: COMPARATOR
Intervention: Wait‐listed control group (n = 252)
Number of subjects: 502
Study: 9886747

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Nondiabetic patients with significant stenosis
Number of subjects: 138

Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 138
Study: 7731414

Group type: EXPERIMENTAL
Intervention: Group A (CF children with symptoms)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group B (CF children without symptoms)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Group C (healthy children)
Number of subjects: 20
Study: 2500055

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sodium chondroitin sulfate-sodium hyaluronate
Number of subjects: 100
Study: 218151

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens and cyclic progesterone
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 31220140

Group type: EXPERIMENTAL
Intervention: SMS reminder intervention
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Second SMS message intervention
Number of subjects: 506

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 506
Study: 28388953

Group type: EXPERIMENTAL
Intervention: Vaccinated with the test product (novel combination vaccine consisting of PCV2 subunits and inactivated M. hyo strain J)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Vaccinated with the test product (novel combination vaccine)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (injected with sterile buffered saline)
Number of subjects: 600
Study: 26302093

Group type: EXPERIMENTAL
Intervention: Eplerenone (100 mg/day for 1 month)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23644038

Group type: EXPERIMENTAL
Intervention: Cognitive therapy for 16 weeks
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Paroxetine treatment for 16 weeks
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 231
Study: 21318601

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 152

Group type: COMPARATOR
Intervention: Conventional dose-dense chemotherapy
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Angiogenesis markers (CD31 and CD105)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Molecular subtypes analysis
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Increased tumor size and positive Her-2 status
Number of subjects: 152
Study: 18448859

Group type: EXPERIMENTAL
Intervention: Omega 3/6 fatty acids (eye q) for 6 months
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 17389292

Group type: EXPERIMENTAL
Intervention: IV IL-2
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: SC IL-2
Number of subjects: 159

Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 159
Study: 15009002

Group type: EXPERIMENTAL
Intervention: Chemotherapy without cranial irradiation
Number of subjects: 14
Study: 11045437

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Valproate (VPA)
Number of subjects: 12
Study: 10203399

Group type: EXPERIMENTAL
Intervention: Model-telephone
Number of subjects: 233

Group type: COMPARATOR
Intervention: No model-telephone (control)
Number of subjects: 233
Study: 8450590

Group type: EXPERIMENTAL
Intervention: Group S (slow training) trained for 8 weeks at 1.05 rad s‐1
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Group F (fast training) trained for 8 weeks at 3.14 rad s‐1
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Group P (periodized training) trained for 5 weeks at 1.05 rad s‐1 and 3 weeks at 3.14 rad s‐1
Number of subjects: 34

Group type: COMPARATOR
Intervention: Group C (control group)
Number of subjects: 34
Study: 3102991

Group type: EXPERIMENTAL
Intervention: GRF (growth hormone-releasing factor)
Number of subjects: 30

Group type: COMPARATOR
Intervention: TRH (thyrotropin-releasing hormone)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GRF plus TRH
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 30
Study: 9310525

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 746

Group type: COMPARATOR
Intervention: Traditional Care
Number of subjects: 746
Study: 30902532

Group type: EXPERIMENTAL
Intervention: Bone Marrow Venting Procedure (BMVP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Meniscal repair only (Control)
Number of subjects: 40
Study: 30056615

Group type: EXPERIMENTAL
Intervention: Functional Family Therapy (FFT)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Alternative family therapy (Control)
Number of subjects: 129
Study: 26511012

Group type: EXPERIMENTAL
Intervention: CPC levels measured at baseline, 3 months, and 12 months
Number of subjects: 117
Study: 24374901

Group type: EXPERIMENTAL
Intervention: sorafenib treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: healthy subjects
Number of subjects: 25
Study: 22745145

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 2x600 mg/day for 8 weeks
Number of subjects: 32
Study: 19622077

Group type: EXPERIMENTAL
Intervention: Rapid MRSA screening
Number of subjects: 12682

Group type: COMPARATOR
Intervention: Standard culture method
Number of subjects: 12682
Study: 17427172

Group type: EXPERIMENTAL
Intervention: Supraselective transarterial chemoembolization (STACE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional transarterial chemoembolization (TACE)
Number of subjects: 60
Study: 15583702

Group type: EXPERIMENTAL
Intervention: COMT Val/Val genotype
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: COMT gene
Number of subjects: 120
Study: 11893973

Group type: EXPERIMENTAL
Intervention: 10 mL 0.5% bupivacaine solution
Number of subjects: 34

Group type: COMPARATOR
Intervention: 10 mL normal saline (placebo)
Number of subjects: 34
Study: 10462334

Group type: EXPERIMENTAL
Intervention: Infection prevention program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 7843752

Group type: COMPARATOR
Intervention: Untreated hypertensive subjects (category II)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subjects with successful antihypertensive therapy (category III)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subjects who remained hypertensive despite drug therapy (category IV)
Number of subjects: 0
Study: 2192572

Group type: EXPERIMENTAL
Intervention: Piritramide 0.1 mg/kg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nalbuphine 0.1 mg/kg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 350940

Group type: EXPERIMENTAL
Intervention: Tocopherol (600 mg/day for 10 days)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 30792343

Group type: EXPERIMENTAL
Intervention: ICS-containing triple therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single or double maintenance therapy
Number of subjects: 0
Study: 28655015

Group type: EXPERIMENTAL
Intervention: Active acupuncture plus clomiphene
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control acupuncture plus clomiphene
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Active acupuncture plus placebo
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control acupuncture plus placebo
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Clomiphene
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control acupuncture
Number of subjects: 1000
Study: 25808103

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg daily for 24 weeks
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo daily for 24 weeks
Number of subjects: 361

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg daily for 12 weeks
Number of subjects: 361

Group type: COMPARATOR
Intervention: Placebo daily for 12 weeks
Number of subjects: 361
Study: 24050532

Group type: EXPERIMENTAL
Intervention: Laparoscopic upper pole heminephroureterectomy (LHNU)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Open surgery upper pole heminephroureterectomy (OHNU)
Number of subjects: 27
Study: 21386088

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT) using transdermal 2% testosterone gel
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study: 18789844

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17542407

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (250 mg dissolved in 5 ml of water orally twice daily for 7 days)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 14718904

Group type: EXPERIMENTAL
Intervention: Chronic low frequency (6 Hz) motor stimulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Submotor transcutaneous electrical nerve (TENS) stimulation
Number of subjects: 30
Study: 11265082

Group type: EXPERIMENTAL
Intervention: Fibrin glue applied to lymphatic structures prior to closure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Closure without fibrin glue
Number of subjects: 0
Study: 9430014

Group type: EXPERIMENTAL
Intervention: Colpermin
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 8516521

Group type: COMPARATOR
Intervention: Morphine 0.075 mg/kg i.v. every 3 hours after operation (Group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral blockade 15 ml of 0.37‐5% bupivacaine with 1:200.000 adrenaline (Group B)
Number of subjects: 20